The Implications of Current Methodological Issues for International Guidance

Statistics in Biopharmaceutical Research

Volumn 5, Issue 3, 2013, Pages 211-222

  Hemmings, Robert J ^a   Lewis, John A ^b  

^a MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^b Silverton Lodge Silverton Lane   (United Kingdom)

Author keywords

Clinical trials; Marketing applications; New medicinal products; Pharmaceutical development; Statistical principles

Indexed keywords

ARTICLE; CONSENSUS DEVELOPMENT; DATA ANALYSIS; DECISION MAKING; HEALTH CARE QUALITY; HYPOTHESIS; ICH E9 GUIDELINE; INTERNAL CONSISTENCY; METHODOLOGY; PHARMACOGENETICS; PHARMACOGENOMICS; PROFESSIONAL STANDARD; STATISTICAL ANALYSIS; STATISTICS;

EID: 84884324390     PISSN: None     EISSN: 19466315     Source Type: Journal    
DOI: 10.1080/19466315.2013.809315     Document Type: Article

References (15)

1. CPMP Working Party on Efficacy of Medicinal Products. 1995. Biostatistical Methodology in Clinical Trials in Applications for Marketing Authorizations for Medicinal Purposes. Statistics in Medicine, 14: 1659 - 1682.
2. European Commission. 2009. " A Guideline on Summary of Product Characteristics ". Available at http://www.emea.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000267.jsp&mid=WC0b01ac05800b378b
3. European Medicines Agency. 1996. " Note for Guidance on Good Clinical Practice ". ICH Topic E6 (R1). Available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002874.pdf
4. European Medicines Agency. 2001. " Points to Consider on Application With 1. Meta-analyses; 2. One Pivotal Study ". CPMP/EWP/2330/99. Available at http://www.emea.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000366.jsp&mid=WC0b01ac0580032ec4
5. European Medicines Agency. 2002. " Points to Consider on Multiplicity Issues in Clinical Trials ". CPMP/EWP/908/99, Available at http://www.emea.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000366.jsp&mid=WC0b01ac0580032ec4
6. European Medicines Agency. 2003. " Questions and Answers, Ethnic Factors in the Acceptability of Foreign Clinical Data ". ICH Topic E5 (R1). Available at http://www.emea.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000366.jsp&mid=WC0b01ac0580032ec4
7. European Medicines Agency. 2007. " Reflection Paper on Methodological Issues in Confirmatory Clinical Trials Planned With an Adaptive Design ". CHMP/EWP/2459/02. Available at http://www.emea.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000366.jsp&mid=WC0b01ac0580032ec4
8. European Medicines Agency. 2010. " Missing Data in Confirmatory Clinical Trials ". CPMP/EWP/1776/99 Rev.1. Available at http://www.emea.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000366.jsp&mid=WC0b01ac0580032ec4
9. ICH E9 Expert Working Group. 1999. Statistical Principles for Clinical Trials: ICH Harmonised Tripartite Guideline. Statistics in Medicine, 18: 1905 - 1942.
10. Lewis, J. 2008. Editorial: 10 Years of E9. Pharmaceutical Statistics, 7: 1 - 3.
11. Lewis, J. A. 1995. Statistical Issues in the Regulation of Medicines. Statistics in Medicine, 14: 127 - 136.
12. Lewis, J. A. 2002. The European Regulatory Experience. Statistics in Medicine, 21: 2931 - 2938.
13. Lewis, J., Louv, W., Rockhold, F. and Sato, T. 2001. The Impact of the Guideline Entitled Statistical Principles for Clinical Trials (ICH E9). Statistics in Medicine, 20: 2549 - 2560.
14. Ministry of Health and Welfare. 1992. " Guideline for the Statistical Analysis of Clinical Trials ". Tokyo, Japan: MHW Pharmaceutical Affairs Bureau. (in Japanese)
15. Panel on Handling Missing Data in Clinical Trials; US National Research Council. 2010. " The Prevention and Treatment of Missing Data in Clinical Trials ". Washington, DC: The National Academies Press. Available at http://www.nap.edu/catalog.php?record_id=12955#orgs